FDA grants orphan drug status to RadioMedix for novel radiotracer

01/6/2014 | PRWeb

RadioMedix announced it has received orphan drug status from the FDA for 68Ga-DOTATATE, or GalioMedix, a PET/CT agent for neuroendocrine tumor imaging. Preliminary tests have showed higher sensitivity and image resolution and rapid results with the new agent.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Director, Site Quality Management
Minneapolis, MN